Authentification abonné
lvrea
Accueil Tous les numéros Volume 27 / Numéro 6 (Novembre 2018) Méd. Intensive Réa., 27 6 (2018) 522-536 Références
Accès gratuit
Numéro
Méd. Intensive Réa.
Volume 27, Numéro 6, Novembre 2018
Néphrologie et métabolisme
Page(s) 522 - 536
Section Mise au point / Update
DOI https://doi.org/10.3166/rea-2018-0070
Publié en ligne 22 novembre 2018
  • Hanahan D, Weinberg RA, (2000) The hallmarks of cancer. Cell 100: 57–70 [CrossRef] [PubMed] [Google Scholar]
  • Hanahan D, Weinberg RA, (2011) Hallmarks of cancer: the next generation. Cell 144: 646–674 [CrossRef] [PubMed] [Google Scholar]
  • Coley WB, (1991) The treatment of malignant tumors by repeated inoculations of erysipelas. With a report of ten original cases. 1893. Clin Orthop 3–11 [Google Scholar]
  • Rouprêt M, Neuzillet Y, Masson-Lecomte A, Colin P, Compérat E, Dubosq F, Houédé N, Larré S, Pignot G, Puech P, Roumiguié M, Xylinas E, Méjean A, (2016) Recommandations en oncourologie 2016–2018 du CCAFU : tumeurs de la vessie. /data/revues/11667087/v27sS1/S1166708716307047/ [Google Scholar]
  • Fridman WH, (2016) Historique de l’immunothérapie. Changement de paradigme ? Bull Cancer (Paris) 103: S122–S126 [CrossRef] [Google Scholar]
  • Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ, Chew A, Gonzalez VE, Zheng Z, Lacey SF, Mahnke YD, Melenhorst JJ, Rheingold SR, Shen A, Teachey DT, Levine BL, June CH, Porter DL, Grupp SA, (2014) Chimeric antigen receptor T-cells for sustained remissions in leukemia. N Engl J Med 371: 1507 [CrossRef] [PubMed] [Google Scholar]
  • Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, Redfern CH, Ferrari AC, Dreicer R, Sims RB, Xu Y, Frohlich MW, Schellhammer PF, (2010) Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 363: 411–422 [CrossRef] [PubMed] [Google Scholar]
  • Kroemer G, Galluzzi L, Kepp O, Zitvogel L, (2013) Immunogenic cell death in cancer therapy. Annu Rev Immunol 31: 51–72 [CrossRef] [PubMed] [Google Scholar]
  • Sapoznik S, Hammer O, Ortenberg R, Besser MJ, Ben-Moshe T, Schachter J, Markel G, (2012) Novel anti-melanoma immunotherapies: disarming tumor escape mechanisms. Clin Dev Immunol. doi: 10.1155/2012/818214 [Google Scholar]
  • Pardoll DM, (2012) The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12: 252–264 [Google Scholar]
  • Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SAJR, Behjati S, Biankin AV, Bignell GR, Bolli N, Borg A, Børresen-Dale AL, Boyault S, Burkhardt B, Butler AP, Caldas C, Davies HR, Desmedt C, Eils R, Eyfjörd JE, Foekens JA, Greaves M, Hosoda F, Hutter B, Ilicic T, Imbeaud S, Imielinsk M, Jäger N, Jones DTW, Jones D, Knappskog S, Kool M, Lakhani SR, López-Otín C, Martin S, Munshi NC, Nakamura H, Northcott PA, Pajic M, Papaemmanuil E, Paradiso A, Pearson JV, Puente XS, Raine K, Ramakrishna M, Richardson AL, Richter J, Rosenstiel P, Schlesner M, Schumacher TN, Span PN, Teague JW, Totoki Y, Tutt ANJ, Valdés-Mas R, van Buuren MM, van ’t Veer L, Vincent-Salomon A, Waddell N, Yates LR, Zucman-Rossi J, Futreal PA, McDermott U, Lichter P, Meyerson M, Grimmond SM, Siebert R, Campo E, Shibata T, Pfister SM, Campbell PJ, Stratton MR, (2013) Signatures of mutational processes in human cancer. Nature 500: 415–421 [CrossRef] [PubMed] [Google Scholar]
  • Lawrence MS, Stojanov P, Polak P, Kryukov GV, Cibulskis K, Sivachenko A, Carter SL, Stewart C, Mermel CH, Roberts SA, Kiezun A, Hammerman PS, McKenna A, Drier Y, Zou L, Ramos AH, Pugh TJ, Stransky N, Helman E, Kim J, Sougnez C, Ambrogio L, Nickerson E, Shefler E, Cortés ML, Auclair D, Saksena G, Voet D, Noble M, DiCara D, Lin P, Lichtenstein L, Heiman DI, Fennell T, Imielinski M, Hernandez B, Hodis E, Baca S, Dulak AM, Lohr J, Landau DA, Wu CJ, Melendez-Zajgla J, Hidalgo-Miranda A, Koren A, McCarroll SA, Mora J, Crompton B, Onofrio R, Parkin M, Winckler W, Ardlie K, Gabriel SB, Roberts CWM, Biegel JA, Stegmaier K, Bass AJ, Garraway LA, Meyerson M, Golub TR, Gordenin DA, Sunyaev S, Lander ES, Getz G, (2013) Mutational heterogeneity in cancer and the search for new cancer genes. Nature 499: 214–218 [CrossRef] [PubMed] [Google Scholar]
  • Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, Skora AD, Luber BS, Azad NS, Laheru D, Biedrzycki B, Donehower RC, Zaheer A, Fisher GA, Crocenzi TS, Lee JJ, Duffy SM, Goldberg RM, de la Chapelle A, Koshiji M, Bhaijee F, Huebner T, Hruban RH, Wood LD, Cuka N, Pardoll DM, Papadopoulos N, Kinzler KW, Zhou S, Cornish TC, Taube JM, Anders RA, Eshleman JR, Vogelstein B, Diaz LAJ, (2015) PD-1 Blockade in tumors with mismatch-repair deficiency. N Engl J Med 372: 2509–2520 [CrossRef] [PubMed] [Google Scholar]
  • Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ, Lee W, Yuan J, Wong P, Ho TS, Miller ML, Rekhtman N, Moreira AL, Ibrahim F, Bruggeman C, Gasmi B, Zappasodi R, Maeda Y, Sander C, Garon EB, Merghoub T, Wolchok JD, Schumacher TN, Chan TA, (2015) Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer. Science 348: 124–128 [Google Scholar]
  • Snyder A, Makarov V, Merghoub T, Yuan J, Zaretsky JM, Desrichard A, Walsh LA, Postow MA, Wong P, Ho TS, Hollmann TJ, Bruggeman C, Kannan K, Li Y, Elipenahli C, Liu C, Harbison CT, Wang L, Ribas A, Wolchok JD, Chan TA, (2014) Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med 371: 2189–2199 [CrossRef] [PubMed] [Google Scholar]
  • Van Allen EM, Miao D, Schilling B, Shukla SA, Blank C, Zimmer L, Sucker A, Hillen U, Foppen MHG, Goldinger SM, Utikal J, Hassel JC, Weide B, Kaehler KC, Loquai C, Mohr P, Gutzmer R, Dummer R, Gabriel S, Wu CJ, Schadendorf D, Garraway LA, (2015) Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science 350: 207–211 [Google Scholar]
  • Hellmann MD, Ciuleanu TE, Pluzanski A, Lee JS, Otterson GA, Audigier-Valette C, Minenza E, Linardou H, Burgers S, Salman P, Borghaei H, Ramalingam SS, Brahmer J, Reck M, O’Byrne KJ, Geese WJ, Green G, Chang H, Szustakowski J, Bhagavatheeswaran P, Healey D, Fu Y, Nathan F, Paz-Ares L, (2018) Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden. N Engl J Med doi: 10.1056/NEJMoa1801946 [Google Scholar]
  • Hellmann MD, Callahan MK, Awad MM, Calvo E, Ascierto PA, Atmaca A, Rizvi NA, Hirsch FR, Selvaggi G, Szustakowski JD, Sasson A, Golhar R, Vitazka P, Chang H, Geese WJ, Antonia SJ, (2018) Tumor mutational burden and efficacy of nivolumab monotherapy and in combination with ipilimumab in small-cell lung cancer. Cancer Cell doi: 10.1016/j.ccell.2018.04.001 [Google Scholar]
  • Pagès F, Granier C, Kirilovsky A, Elsissy C, Tartour E, (2016) Biomarqueurs prédictifs de réponse aux traitements bloquant les voies de costimulation inhibitrices. Bull Cancer (Paris) 103: S151–S159 [CrossRef] [Google Scholar]
  • Fridman WH, Pagès F, Sautès-Fridman C, Galon J, (2012) The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer 12: 298–306 [Google Scholar]
  • Ji RR, Chasalow SD, Wang L, Hamid O, Schmidt H, Cogswell J, Alaparthy S, Berman D, Jure-Kunkel M, Siemers NO, Jackson JR, Shahabi V, (2012) An immune-active tumor microenvironment favors clinical response to ipilimumab. Cancer Immunol Immunother 61: 1019–1031 [CrossRef] [PubMed] [Google Scholar]
  • Hamid O, Schmidt H, Nissan A, Ridolfi L, Aamdal S, Hansson J, Guida M, Hyams DM, Gómez H, Bastholt L, Chasalow SD, Berman D, (2011) A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma. J Transl Med 9: 204 [CrossRef] [PubMed] [Google Scholar]
  • Diem S, Schmid S, Krapf M, Flatz L, Born D, Jochum W, Templeton AJ, Früh M, (2017) Neutrophil-to-Lymphocyte Ratio (NLR) and Platelet-to-Lymphocyte Ratio (PLR) as prognostic markers in patients with Non-Small Cell Lung Cancer (NSCLC) treated with nivolumab. Lung Cancer Amst Neth 111: 176–181 [CrossRef] [Google Scholar]
  • Blackley E, Lim LE, Moore M, Voskoboynik M, McLean C, Haydon A, (2017) 1242PNeutrophil to Lymphocyte Ratio (NLR) as an independent prognostic measure in patients receiving targeted therapy or immunotherapy for stage IV melanoma. Ann Oncol doi: 10.1093/annonc/mdx377.028 [Google Scholar]
  • Mezquita L, Auclin E, Ferrara R, Charrier M, Remon J, Planchard D, Ponce S, Ares LP, Leroy L, Audigier-Valette C, Felip E, Zerón-Medina J, Garrido P, Brosseau S, Zalcman G, Mazieres J, Caramela C, Lahmar J, Adam J, Chaput N, Soria JC, Besse B, (2018) Association of the Lung Immune Prognostic Index with immune checkpoint inhibitor outcomes in patients with advanced Non-Small Cell Lung Cancer. JAMA Oncol 4: 351–357 [CrossRef] [PubMed] [Google Scholar]
  • Hodi FS, Butler M, Oble DA, Seiden MV, Haluska FG, Kruse A, MacRae S, Nelson M, Canning C, Lowy I, Korman A, Lautz D, Russell S, Jaklitsch MT, Ramaiya N, Chen TC, Neuberg D, Allison JP, Mihm MC, Dranoff G, (2008) Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyteassociated antigen 4 in previously vaccinated cancer patients. Proc Natl Acad Sci U S A 105: 3005–3010 [CrossRef] [PubMed] [Google Scholar]
  • Seymour L, Bogaerts J, Perrone A, Ford R, Schwartz LH, Mandrekar S, Lin NU, Litière S, Dancey J, Chen A, Hodi FS, Therasse P, Hoekstra OS, Shankar LK, Wolchok JD, Ballinger M, Caramella C, Vries EGE de, (2017) iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol 18: e143–e152 [CrossRef] [PubMed] [Google Scholar]
  • Wolchok JD, Hoos A, O’Day S, Weber JS, Hamid O, Lebbé C, Maio M, Binder M, Bohnsack O, Nichol G, Humphrey R, Hodi FS, (2009) Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 15: 7412–7420 [CrossRef] [PubMed] [Google Scholar]
  • Chiou VL, Burotto M, (2015) Pseudoprogression and immunerelated response in solid tumors. J Clin Oncol 33: 3541–3543 [CrossRef] [PubMed] [Google Scholar]
  • Kurra V, Sullivan RJ, Gainor JF, Hodi FS, Gandhi L, Sadow CA, Harris GJ, Flaherty K, Lee S, (2016) Pseudoprogression in cancer immunotherapy: rates, time course and patient outcomes. J Clin Oncol 34 [Google Scholar]
  • Michot JM, Bigenwald C, Champiat S, Collins M, Carbonnel F, Postel-Vinay S, Berdelou A, Varga A, Bahleda R, Hollebecque A, Massard C, Fuerea A, Ribrag V, Gazzah A, Armand JP, Amellal N, Angevin E, Noel N, Boutros C, Mateus C, Robert C, Soria JC, Marabelle A, Lambotte O, (2016) Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur J Cancer 54: 139–148 [CrossRef] [PubMed] [Google Scholar]
  • Naidoo J, Page DB, Li BT, Connell LC, Schindler K, Lacouture ME, Postow MA, Wolchok JD, (2015) Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. Ann Oncol 26: 2375–2391 [PubMed] [Google Scholar]
  • Naidoo J, Wang X, Woo KM, Iyriboz T, Halpenny D, Cunningham J, Chaft JE, Segal NH, Callahan MK, Lesokhin AM, Rosenberg J, Voss MH, Rudin CM, Rizvi H, Hou X, Rodriguez K, Albano M, Gordon RA, Leduc C, Rekhtman N, Harris B, Menzies AM, Guminski AD, Carlino MS, Kong BY, Wolchok JD, Postow MA, Long GV, Hellmann MD, (2017) Pneumonitis in patients treated with anti-programmed death-1/programmed death ligand 1 therapy. J Clin Oncol 35: 709–717 [CrossRef] [PubMed] [Google Scholar]
  • Nishino M, Giobbie-Hurder A, Hatabu H, Ramaiya NH, Hodi FS, (2016) Incidence of programmed cell death 1 inhibitor–related pneumonitis in patients with advanced cancer: a systematic review and meta-analysis. JAMA Oncol 2: 1607–1616 [CrossRef] [PubMed] [Google Scholar]
  • Hodi FS, Lee S, McDermott DF, Rao UN, Butterfield LH, Tarhini AA, Leming P, Puzanov I, Shin D, Kirkwood JM, (2014) Ipilimumab plus sargramostim vs ipilimumab alone for treatment of metastatic melanoma: a randomized clinical trial. JAMA 312: 1744–1753 [CrossRef] [PubMed] [Google Scholar]
  • Tirumani SH, Ramaiya NH, Keraliya A, Bailey ND, Ott PA, Hodi FS, Nishino M, (2015) Radiographic profiling of immunerelated adverse events in advanced melanoma patients treated with ipilimumab. Cancer Immunol Res 3: 1185–1192 [CrossRef] [PubMed] [Google Scholar]
  • Delaunay M, Cadranel J, Lusque A, Meyer N, Gounant V, Moro-Sibilot D, Michot JM, Raimbourg J, Girard N, Guisier F, Planchard D, Metivier AC, Tomasini P, Dansin E, Pérol M, Campana M, Gautschi O, Früh M, Fumet JD, Audigier-Valette C, Couraud S, Dalle S, Leccia MT, Jaffro M, Collot S, Prévot G, Milia J, Mazieres J, (2017) Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients. Eur Respir J 50: 1700050 [CrossRef] [PubMed] [Google Scholar]
  • Nishino M, Ramaiya NH, Awad MM, Sholl LM, Maattala JA, Taibi M, Hatabu H, Ott PA, Armand PF, Hodi FS, (2016) PD-1 inhibitor– related pneumonitis in advanced cancer patients: radiographic patterns and clinical course. Clin Cancer Res 22: 6051–6060 [CrossRef] [PubMed] [Google Scholar]
  • Haanen JBAG, Carbonnel F, Robert C, Kerr KM, Peters S, Larkin J, Jordan K; on behalf of the ESMO Guidelines Committee, (2017) Management of toxicities from immunotherapy: ESMO clinical practice guidelines for diagnosis, treatment and followup. Ann Oncol 28: iv119–iv142 [CrossRef] [PubMed] [Google Scholar]
  • Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, Leming PD, Spigel DR, Antonia SJ, Horn L, Drake CG, Pardoll DM, Chen L, Sharfman WH, Anders RA, Taube JM, McMiller TL, Xu H, Korman AJ, Jure-Kunkel M, Agrawal S, McDonald D, Kollia GD, Gupta A, Wigginton JM, Sznol M, (2012) Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366: 2443–2454 [Google Scholar]
  • Nishino M, Sholl LM, Hatabu H, Ramaiya NH, Hodi FS, (2015) Anti-PD-1-related pneumonitis during cancer immunotherapy. N Engl J Med 373: 288–290 [CrossRef] [PubMed] [Google Scholar]
  • Collins M, Michot JM, Danlos FX, Mussini C, Soularue E, Mateus C, Loirat D, Buisson A, Rosa I, Lambotte O, Laghouati S, Chaput N, Coutzac C, Voisin AL, Soria JC, Marabelle A, Champiat S, Robert C, Carbonnel F, (2017) Inflammatory gastrointestinal diseases associated with PD-1 blockade antibodies. Ann Oncol 28: 2860–2865 [CrossRef] [PubMed] [Google Scholar]
  • Cramer P, Bresalier RS, (2017) Gastrointestinal and hepatic complications of immune checkpoint inhibitors. Curr Gastroenterol Rep 19: 3 [CrossRef] [PubMed] [Google Scholar]
  • Faje A, (2016) Immunotherapy and hypophysitis: clinical presentation, treatment, and biologic insights. Pituitary 19: 82–92 [CrossRef] [PubMed] [Google Scholar]
  • Faje AT, Sullivan R, Lawrence D, Tritos NA, Fadden R, Klibanski A, Nachtigall L, (2014) Ipilimumab-induced hypophysitis: a detailed longitudinal analysis in a large cohort of patients with metastatic melanoma. J Clin Endocrinol Metab 99: 4078–4085 [CrossRef] [PubMed] [Google Scholar]
  • Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, Schadendorf D, Dummer R, Smylie M, Rutkowski P, Ferrucci PF, Hill A, Wagstaff J, Carlino MS, Haanen JB, Maio M, Marquez-Rodas I, McArthur GA, Ascierto PA, Long GV, Callahan MK, Postow MA, Grossmann K, Sznol M, Dreno B, Bastholt L, Yang A, Rollin LM, Horak C, Hodi FS, Wolchok JD, (2015) Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 373: 23–34 [CrossRef] [PubMed] [Google Scholar]
  • Postow MA, (2015) Managing immune checkpoint-blocking antibody side effects. Am Soc Clin Oncol Educ Book Am Soc Clin Oncol Meet 76–83 [CrossRef] [Google Scholar]
  • Joly P, Roujeau JC, Benichou J, Picard C, Dreno B, Delaporte E, Vaillant L, D’Incan M, Plantin P, Bedane C, Young P, Bernard P, (2002) A comparison of oral and topical corticosteroids in patients with bullous pemphigoid. N Engl J Med 346: 321–327 [CrossRef] [PubMed] [Google Scholar]
  • Naidoo J, Schindler K, Querfeld C, Busam K, Cunningham J, Page DB, Postow MA, Weinstein A, Lucas AS, Ciccolini KT, Quigley EA, Lesokhin AM, Paik PK, Chaft JE, Segal NH, D’Angelo SP, Dickson MA, Wolchok JD, Lacouture ME, (2016) Autoimmune bullous skin disorders with immune checkpoint inhibitors targeting PD-1 and PD-L1. Cancer Immunol Res 4: 383–389 [CrossRef] [PubMed] [Google Scholar]
  • Mahmood SS, Fradley MG, Cohen JV, Nohria A, Reynolds KL, Heinzerling LM, Sullivan RJ, Damrongwatanasuk R, Chen CL, Gupta D, Kirchberger MC, Awadalla M, Hassan MZO, Moslehi JJ, Shah SP, Ganatra S, Thavendiranathan P, Lawrence DP, Groarke JD, Neilan TG, (2018) Myocarditis in patients treated with immune checkpoint inhibitors. J Am Coll Cardiol 71: 1755–1764 [CrossRef] [PubMed] [Google Scholar]
  • Johnson DB, Balko JM, Compton ML, Chalkias S, Gorham J, Xu Y, Hicks M, Puzanov I, Alexander MR, Bloomer TL, Becker JR, Slosky DA, Phillips EJ, Pilkinton MA, Craig-Owens L, Kola N, Plautz G, Reshef DS, Deutsch JS, Deering RP, Olenchock BA, Lichtman AH, Roden DM, Seidman CE, Koralnik IJ, Seidman JG, Hoffman RD, Taube JM, Diaz LAJ, Anders RA, Sosman JA, Moslehi JJ, (2016) Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med 375: 1749–1755 [CrossRef] [PubMed] [Google Scholar]
  • Postow MA, Chesney J, Pavlick AC, Robert C, Grossmann K, McDermott D, Linette GP, Meyer N, Giguere JK, Agarwala SS, Shaheen M, Ernstoff MS, Minor D, Salama AK, Taylor M, Ott PA, Rollin LM, Horak C, Gagnier P, Wolchok JD, Hodi FS, (2015) Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med 372: 2006–2017 [CrossRef] [PubMed] [Google Scholar]
  • Kroemer G, Senovilla L, Galluzzi L, André F, Zitvogel L, (2015) Natural and therapy-induced immunosurveillance in breast cancer. Nat Med 21: 1128–1138 [CrossRef] [PubMed] [Google Scholar]
  • Chen DS, Mellman I, (2013) Oncology meets immunology: the cancer-immunity cycle. Immunity 39: 1–10 [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  • Gordon MS, Margolin K, Talpaz M, Sledge GW, Holmgren E, Benjamin R, Stalter S, Shak S, Adelman D, (2001) Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol 19: 843–850 [CrossRef] [PubMed] [Google Scholar]
  • Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, Chau I, Van Cutsem E, (2004) Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351: 337–345 [CrossRef] [PubMed] [Google Scholar]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.